tradingkey.logo

tradingkey.logo
怜玢


BioXcel Therapeutics Inc

BTAI
りォッチリストに远加
0.009USD
-0.001-10.00%
終倀 09-04 16:00ET
281.79K時䟡総額
損倱額盎近12ヶ月PER

BioXcel Therapeutics Incに぀いお 䌁業名

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

BioXcel Therapeutics Inc プロフィヌル


䌁業コヌドBTAI
䌚瀟名BioXcel Therapeutics Inc
䞊堎日Mar 08, 2018
最高経営責任者「CEO」Mehta (Vimal)
埓業員数37
蚌刞皮類Ordinary Share
決算期末Mar 08
本瀟所圚地555 Long Wharf Dr
郜垂NEW HAVEN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号06511-6107
電話番号12036438060
りェブサむトhttps://www.bioxceltherapeutics.com/
䌁業コヌドBTAI
䞊堎日Mar 08, 2018
最高経営責任者「CEO」Mehta (Vimal)

BioXcel Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
Director
Director
550.28K
+0.04%
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
Director
Director
550.28K
+0.04%
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
Director
Director
550.28K
+0.04%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
26.84K
+0.13%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
26.34K
+0.13%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
20.32K
+0.00%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
20.32K
+0.00%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
20.32K
+0.00%
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
11.69K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
11.69K
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
Director
Director
550.28K
+0.04%
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
Director
Director
550.28K
+0.04%
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
Director
Director
550.28K
+0.04%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
26.84K
+0.13%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
26.34K
+0.13%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
20.32K
+0.00%

よくある質問

BioXcel Therapeutics Incの䞊䜍5名の株䞻は誰ですか


BioXcel Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Vimal Mehta, Ph.D.

BioXcel Therapeutics IncBTAIの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、BioXcel Therapeutics Incの株匏を保有しおいる機関は151瀟あり、保有株匏の総垂堎䟡倀は玄4.05Mで、党䜓の14.97%を占めおいたす。2025Q4ず比范しお、機関の持ち株は972388.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。